Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1
Cell Biology International · 2025
DOI: 10.1002/cbin.70032 ↗At a glance
Journal article in Cell Biology International, 2025. Written by Tianye Yang and 4 co-authors. Institution: Department of Emergency, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. Major MEDLINE topics: Catechin, Prostatic Hyperplasia, Insulin-Like Growth Factor I. Cited 6 times so far (Crossref); 43 references. Funded by: The work was sponsored by the Interdisciplinary Program of Shanghai Jiao Tong University (Project Number YG2024QNB17) and the National Natural Science Foundati….
Abstract (original language)
Benign prostatic hyperplasia (BPH), a prevalent age‐related condition in men, is increasingly linked to metabolic syndrome (MetS) and gut microbiota dysbiosis. This study reveals how Firmicutes‐dominant microbial imbalance drives BPH progression via IGF‐1 signaling and identifies the green tea polyphenol epigallocatechin‐3‐gallate (EGCG) as a dual‐action therapeutic. Using MetS‐BPH mouse models and human prostate cell lines, we demonstrated that BPH‐associated gut microbiota—particularly elevated Firmicutes and an increased Firmicutes/Bacteroidetes ratio—promotes prostate hyperplasia by upregulating IGF‐1. Both BPH mice and recipient mice transplanted with BPH microbiota showed elevated serum and prostate IGF‐1 levels, mirroring findings in human BPH patients. Mechanistically, IGF‐1 stimulated prostate cell proliferation (RWPE‐1/WPMY‐1) and suppressed apoptosis via PI3K/AKT/mTOR activation, while the IGF‐1 antagonist Linsitinib reversed these effects. EGCG emerged as a potent modulator of this gut‐prostate axis: it selectively reduced Firmicutes overgrowth in BPH mice, normalized IGF‐1 levels, and inhibited downstream PI3K/AKT/mTOR signaling. In fecal microbiota transplantation experiments, EGCG counteracted IGF‐1‐driven prostate enlargement and microbial dysbiosis, underscoring its dual role in rebalancing gut flora and blocking growth factor pathways. Our findings position EGCG as a promising intervention for MetS‐associated BPH, simultaneously targeting microbial dysbiosis and IGF‐1 signaling. This study not only elucidates the Firmicutes–IGF‐1 axis in BPH pathogenesis but also highlights the therapeutic potential of dietary polyphenols in metabolic urological disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Emergency, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
- Department of Urology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID profiles: Meng Gu
Funding
- The work was sponsored by the Interdisciplinary Program of Shanghai Jiao Tong University (Project Number YG2024QNB17) and the National Natural Science Foundati…
Cite
APA
Yang, T., Shao, Y., Wang, Z., Liu, C., & Gu, M. (2025). Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1. Cell Biology International. https://doi.org/10.1002/cbin.70032
Vancouver
Yang T, Shao Y, Wang Z, Liu C, Gu M. Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1. Cell Biology International. 2025. doi:10.1002/cbin.70032
BibTeX
@article{Yang2025,
author = {Yang, Tianye and Shao, YiQun and Wang, Zhong and Liu, Chong and Gu, Meng},
title = {Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70032}
}
EUVIMED